3-Year Outcomes of iStent Implant Combined With Phacoemulsification in Asian Eyes With Glaucoma: A Multidimensional Surgical Success Analysis

PURPOSE: To evaluate the long-term performance of combined phacoemulsification and iStent implantation (iStent, iStent inject, and iStent inject W) in Asian patients with glaucoma and cataracts. PATIENTS AND METHODS: This retrospective study included patients who underwent combined phacoemulsification and iStent implantation at a single tertiary center from November 2016 to July 2021. Eyes with varying glaucoma subtypes and severities were included. Changes in mean intraocular pressure (IOP) and the number of glaucoma medications were assessed at baseline and postoperative months (POM) 6, 12, 24, and 36. Surgical success was evaluated using multiple definitions, including complete and qualified success (CS/QS) criteria for IOP ≤18 and ≤15 mm Hg, modified success criteria (anyIOP, anyMed, or IOPMed), and the AAO-recommended criteria. RESULTS: A total of 284 eyes (mean age 70.8±8.9 y) had preoperative IOP of 15.8±3.9 mm Hg on 1.6±0.8 medications. At POM 36, mean IOP reduction was 1.4 mm Hg ( P